GSK scores 51/100 (Making progress) on SINK's independent climate assessment — scored from public data only, no company payment can change a number. Last verified October 2026.
That places GSK joint 120th of 809 companies scored, and 3rd of 15 in Healthcare / Pharmaceuticals.
GSK has credible climate infrastructure: verified Scope 1&2 data, SBTi-validated net-zero to 2045, and sector-leading nature disclosures. But the company is tracking only 12% of its required 80% emissions cut by 2030. Supply chain data gaps, 49% waste circularity (vs 100% target), and trade association misalignment on EU climate policy expose the gap between commitment and delivery.
Every supplier scored from public evidence like this, ranked, in 48 hours. No questionnaires, and your suppliers never know.
This score uses public evidence only. Challenge any question for free, or ask for a human review of evidence you haven't published.
Same ten questions for every company. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × ScaleStrongest on Carbon Footprint — Operations and Energy Source (8/10, 8/10). Weakest on Emissions Trajectory and Resource Use & Waste (5/10, 6/10).
19 sources used in this assessment. All publicly available. Each row shows which rubric questions it informed.
13 of 19 sources are third-party verified or public record.
“Total scope 1 and 2 market-based emissions (metric tonnes CO2e) 763,998 · 714,786 · 644,639 · 563,959”
“the data addresses energy, CO2 emissions, water consumption, wastewater and quality, waste and other”
“The 2024 information underlying the Responsible Business Performance Rating has been subject to limited assurance by Deloitte”
“Since then, we have been working on an annual basis to update the tool and integrate the results within a Power BI dashboard”
“GSK's scope 3 reduction targets exclude emissions related to its purchase of capital goods (buildings and equipment) and its investments”
“From our baseline year in 2020 to 2024 (latest available data), we have reduced carbon emissions by 17 % across all scopes”
“This includes a commitment as part of the RE100 initiative to 100% purchased renewable electricity by 2025”
“This agreement will facilitate the supply of 200 GWh of renewable electricity certificates per year”
“pharmaceutical giant GSK became the first corporate to officially announce it would publish disclosures in line with the TNFD recommendations”
“The Science Based Targets Network (SBTN) has announced that Kering, GSK, and Holcim are the first companies to publicly adopt science-based targets for nature”
“Our total estimated water footprint was 218 million m3.”
“We will achieve zero operational waste through a 20% reduction in the amount of both hazardous and non-hazardous waste we generate”
“All plastic waste including packaging is treated in line with Extended Producer Responsibility (EPR) obligations.”
“GSK already met its 20% water reduction goal in 2022, but has continued to reduce its overall water use by 28% from its 2020 baseline.”
“A 624m3/d wastewater treatment plant handling discharge from the Jurong facility owned by pharmaceuticals and biochemistry giant GSK”
“The Science Based Target initiative (SBTi) has approved GSK's net zero target for 2045 in line with their Corporate Net-Zero Standard”
“GSK and VW said they were aware of the greenwashing risk and the need to prioritize emission avoidance and reduction ahead of offsetting.”
“The GSK Executive Committee (ExCom) is accountable for delivering progress against the metrics and regularly reviews performance”
“GSK is a member of several influential industry associations, including the German Chemical Industry Association (VCI), which takes negative positions on several key EU climate policies.”
If you believe a source has been misread or a newer version exists, submit a challenge.
Where GSK sits among healthcare / pharmaceuticals peers.
Among the 15 major healthcare / pharmaceuticals brands we've scored, GSK sits 3rd of 15.
GSK's score has moved from 50 to 51 across 2 recorded reviews — up 1 point.
Aggregator-citation sweep: broker citations replaced with the primary disclosures they mirror, re-scored through the guarded pipeline under pinned code 9196601.
Initial score at platform launch
This score is not currently being contested.
Every challenge is published. We'd rather be corrected than wrong — that's the whole point.
No challenges submitted yet. If you have evidence that contradicts this score, you can challenge any question above — cite a public source and we'll review it.
GlaxoSmithKline is a multinational pharmaceutical and biotechnology manufacturer headquartered in London, with operations spanning drug development, manufacturing, and vaccines. It is one of the world's largest pharmaceutical companies by revenue, competing with Pfizer, Roche, and Novartis in primary care, oncology, and vaccines.
Peer pharmaceutical manufacturer; comparable scale and product portfolio in primary care and oncology.
View breakdown →Competitor in vaccines, primary care, oncology; comparable scale and manufacturing footprint.
View breakdown →Competitor pharmaceutical and diagnostics company; similar market position and supply chain complexity.
View breakdown →Peer pharmaceutical manufacturer; operates in similar therapeutic areas and geographic markets.
View breakdown →Email alerts when a rubric question is verified, a challenge is resolved, or the overall score changes.
One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
No spam. Unsubscribe in one click.
Checking a company?
Search free →Checking your suppliers?
Get your list scored in 48 hours →Been scored?
See what's behind your number →Nobody can pay us to change a number.